COVID-19: Clinical aspects and therapeutics responses
文献类型：期刊论文
| 作者 | Khan, Suliman7; Ali, Ashaq8,9; Shi, Hongwei10; Siddique, Rabeea7; Shabana8,9; Nabi, Ghulam2; Hu, Junjie1; Wang, Tiejun5; Dong, Men8,9; Zaman, Wajid4 |
| 刊名 | SAUDI PHARMACEUTICAL JOURNAL
 |
| 出版日期 | 2020 |
| 卷号 | 28期号:8页码:1004-1008 |
| 关键词 | COVID-19 Therapeutics Mild symptoms TCM Recoveries |
| ISSN号 | 1319-0164 |
| DOI | 10.1016/j.jsps.2020.06.022 |
| 文献子类 | Article |
| 英文摘要 | COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retro-spective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recov-ery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| 学科主题 | Pharmacology & Pharmacy |
| 出版地 | AMSTERDAM |
| 电子版国际标准刊号 | 2213-7475 |
| WOS关键词 | CORONAVIRUS ; PNEUMONIA ; MEDICINE |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000557427600013 |
| 出版者 | ELSEVIER |
| 资助机构 | Second Affiliated Hospital of Zhengzhou University, Zhengzhou China ; Chinese Postdoctoral Science FoundationChina Postdoctoral Science Foundation |
| 源URL | [http://ir.ibcas.ac.cn/handle/2S10CLM1/21637]  |
| 专题 | 植物研究所_系统与进化植物学研究中心_系统与进化植物学研究中心_学位论文 |
| 作者单位 | 1.Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Pro, Shijiazhuang 050024, Hebei, Peoples R China 2.Wuhan Univ, Sch Life Sci, Key State Lab Virol, Wuhan, Peoples R China 3.Chinese Acad Sci, Inst Bot, State Key Lab Systemat & Evolutionary Bot, Beijing 100093, Peoples R China 4.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Breast Surg, Wuhan, Peoples R China 5.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China 6.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan, Peoples R China 7.Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China 8.Henan Med Key Lab Translat Cerebrovasc Dis, Zhengzhou, Peoples R China 9.Chinese Acad Sci, Wuhan Inst Virol, Xiao Hong Shan 44, Wuhan, Peoples R China 10.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | Khan, Suliman,Ali, Ashaq,Shi, Hongwei,et al. COVID-19: Clinical aspects and therapeutics responses[J]. SAUDI PHARMACEUTICAL JOURNAL,2020,28(8):1004-1008. |
| APA | Khan, Suliman.,Ali, Ashaq.,Shi, Hongwei.,Siddique, Rabeea.,Shabana.,...&Han, Guang.(2020).COVID-19: Clinical aspects and therapeutics responses.SAUDI PHARMACEUTICAL JOURNAL,28(8),1004-1008. |
| MLA | Khan, Suliman,et al."COVID-19: Clinical aspects and therapeutics responses".SAUDI PHARMACEUTICAL JOURNAL 28.8(2020):1004-1008. |
入库方式： OAI收割
来源：植物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。